This article is more than 5 years old. Information may no longer be current.
4D Molecular Therapeutics teams with Foundation Fighting Blindness to develop gene therapies
Click Here to Manage Email Alerts
4D Molecular Therapeutics announced a partnership with Foundation Fighting Blindness to develop intravitreal gene therapeutics for patients with inherited retinal degenerations and dry age-related macular degeneration.
4D Molecular Therapeutics will provide access to its vector technology and manufacturing capabilities, and Foundation Fighting Blindness will identify potential academic and business collaborators, according to a press release.
The intravitreal gene therapeutics will be developed using 4D Molecular Therapeutics’ proprietary adeno-associated virus vectors. Vector technologies can lead to the successful use of gene therapies for inherited retinal degenerations to target affected cells in the retina, according to the release.
“We are very impressed with 4D’s vector evolution approach, the company’s product pipeline and manufacturing expertise. The potential is great for developing a number of gene therapeutics that could treat those affected by retinitis pigmentosa and allied conditions using a simple intravitreal injection approach,” Patricia Zilliox PhD, chief drug development officer at Foundation Fighting Blindness, said in the release.
The release said the two organizations will jointly review and approve all programs associated with the partnership.